Among cancer patients with a positive mSEPT9 or CEA before operation, only about half of them (46.8% and 46.7%, respectively) turned negative within 6-months after surgery, suggesting both markers may not be sensitive enough for monitoring early treatment response. The gene discussed is CEACAM5; the disease is cancer.